Caresyntax closed a $180 million Series C extension round, bringing its Series C fundraising total to $310 million. The company sells AI-based precision surgery technology that unifies operating room data on a single platform.
This will require continued investment in the foundational science to elucidate remaining unknowns regarding how pain works in the body and brain, which in turn can direct us to even more targeted strategies to address the physiology behind specific pain types.
Medical device companies that leverage today's technology to better share and track product and safety information will outpace rivals and gain a competitive edge. They will be the innovators that can solve problems faster and streamline their workflows for optimal efficiency.
NOWDiagnostics' First to Know has FDA De Novo marketing authorization as a new test for syphilis. The at-home product needs only a single drop of blood to test for this sexually transmitted infection.
In this episode, we're joined by Stacey Missmer, professor and associate chair for epidemiology and translational research at the University of Michigan. She discusses a report she recently co-authored that calls on the NIH to improve research on chronic conditions affecting women.
No comments